Free Trial
NASDAQ:ARTV

Artiva Biotherapeutics (ARTV) Stock Price, News & Analysis

Artiva Biotherapeutics logo
$2.47 +0.02 (+0.82%)
Closing price 04/25/2025 04:00 PM Eastern
Extended Trading
$2.44 -0.03 (-1.01%)
As of 04/25/2025 06:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Artiva Biotherapeutics Stock (NASDAQ:ARTV)

Key Stats

Today's Range
$2.36
$2.52
50-Day Range
$1.84
$6.25
52-Week Range
$1.78
$17.31
Volume
247,548 shs
Average Volume
174,437 shs
Market Capitalization
$60.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.40
Consensus Rating
Buy

Company Overview

Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma. It also develops AB-201, an allogeneic anti- human epidermal growth factor receptor 2 chimeric antigen receptor (CAR)-NK cell product candidate; and AB-205, an allogeneic anti-CD5 CAR-NK cell product candidate. The company was incorporated in 2019 and is headquartered in San Diego, California.

Receive ARTV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Artiva Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ARTV Stock News Headlines

Crypto’s crashing…but we’re still profiting
Most traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…
See More Headlines

ARTV Stock Analysis - Frequently Asked Questions

Artiva Biotherapeutics' stock was trading at $10.08 at the start of the year. Since then, ARTV shares have decreased by 75.5% and is now trading at $2.47.
View the best growth stocks for 2025 here
.

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) posted its earnings results on Tuesday, November, 12th. The company reported ($0.92) EPS for the quarter, missing the consensus estimate of ($0.68) by $0.24.

Artiva Biotherapeutics (ARTV) raised $167 million in an initial public offering on Friday, July 19th 2024. The company issued 13,920,000 shares at $12.00 per share.

Shares of ARTV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Artiva Biotherapeutics investors own include AST SpaceMobile (ASTS), Tempus AI (TEM), Delcath Systems (DCTH), Advanced Micro Devices (AMD), AngioDynamics (ANGO), Broadcom (AVGO) and Genius Sports (GENI).

Company Calendar

Last Earnings
11/12/2024
Today
4/26/2025
Next Earnings (Estimated)
6/23/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ARTV
Previous Symbol
NASDAQ:ARTV
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.40
High Stock Price Target
$23.00
Low Stock Price Target
$18.00
Potential Upside/Downside
+725.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$251,000.00
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$60.18 million
Optionable
N/A
Beta
N/A
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ARTV) was last updated on 4/27/2025 by MarketBeat.com Staff
From Our Partners